# Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

> **NCT02721043** · PHASE1 · COMPLETED · sponsor: **Nina Bhardwaj** · enrollment: 13 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **BIOLOGICAL:** Peptides
- **DRUG:** Poly-ICLC
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT02721043
- **Lead sponsor:** Nina Bhardwaj
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2019-11-12
- **Final completion:** 2020-06-08
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2021-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02721043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02721043, "Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02721043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*